Prior Psychedelic Use and Diagnosis Predict Support for PAT: Small Survey Insights

Prior Psychedelic Use and Diagnosis Linked to Support for PAT

A cross-sectional survey published in November 2026 (OpenAlex W7225205185) reports that adults with prior psychedelic use or a self-reported mental health diagnosis are significantly more likely to support and recommend psychedelic-assisted therapy (PAT) than those without such experiences. The study, which included 99 U.S. adults recruited via social media and text messages, found that respondents with previous psychedelic use (n = 34) had a higher mean willingness to recommend PAT (3.65 vs 2.40, P = .0017) and greater support for therapeutic legalization (8.79 vs 7.61, P = .0018) compared to those without prior use. Similarly, individuals with a mental health diagnosis (n = 56) were more willing to recommend PAT (3.88 vs 2.02, P < .001) than those without a diagnosis. Healthcare worker status did not predict attitudes toward PAT in this sample.

Mechanisms: Experience and Diagnosis Shape Attitudes

Prior personal experience with psychedelics and a history of mental health diagnosis appear to shape openness to PAT, possibly by reducing stigma and increasing perceived relevance or urgency. The survey's finding that both groups—those with psychedelic experience and those with a diagnosis—were more willing to recommend PAT suggests that lived experience, whether through direct exposure to psychedelics or through the challenges of mental health conditions, may foster greater receptivity to novel therapeutic approaches. Notably, interest in alternatives to daily medication was high across all groups (mean 4.16 vs 4.18, P = .925), indicating broad curiosity about nontraditional treatments even among those without a diagnosis or psychedelic experience.

Policy and Research Implications: Caution and Opportunity

The study's results offer preliminary insight into the social dynamics that may influence the adoption and acceptance of PAT, but its methodological limitations—small sample size, nonrandom convenience sampling, and reliance on self-reported data—restrict its policy relevance. Policymakers and clinicians should be cautious in extrapolating these findings to the general population or to specific subgroups such as healthcare professionals, given that healthcare worker status was not associated with attitudes in this sample. The study highlights the need for larger, representative surveys and mixed-methods research to understand how education, clinical exposure, and counseling shape informed engagement with PAT. A non-obvious implication is that educational interventions targeting those without prior psychedelic experience or diagnosis may be especially important for broadening acceptance and ensuring equitable access if PAT becomes more widely available.

Risks, Unknowns, and the Limits of Self-Reported Data

The survey's design introduces several sources of bias, including selection bias—participants were recruited via social media and text messaging, potentially skewing the sample toward younger, more digitally connected, or more pro-psychedelic individuals. Self-reported diagnoses and substance use histories may be inaccurate or incomplete, and the cross-sectional nature of the study precludes any causal inference between experience, diagnosis, and attitudes. There is also a risk that early adopters' enthusiasm could outpace evidence, leading to advocacy or demand for PAT before safety and efficacy are fully established in diverse populations. These limitations underscore the importance of rigorous, longitudinal studies and the integration of objective clinical and demographic data.

Outlook: Informing Future Engagement with PAT

As the field of psychedelic-assisted therapy advances, understanding the factors that drive support and willingness to recommend these treatments will be crucial for responsible adoption and policy development. This survey provides an early signal that personal experience and diagnosis status may be key drivers of positive attitudes toward PAT, but robust evidence is needed to guide education, regulation, and clinical practice. Stakeholders should prioritize research that examines how information, clinical exposure, and counseling influence attitudes, especially among those with limited prior exposure to psychedelics or mental health care. The next phase of research should focus on representative sampling and the inclusion of objective measures to inform the equitable and evidence-based rollout of PAT.

By Dr. Alex M. Carter, PhD (Behavioral Science). Reviewed by Dr. Jamie Lin, MD, November 2026. This analysis draws on primary survey data as published in OpenAlex W7225205185 and was reviewed for accuracy and balance by a board-certified psychiatrist.